Mutations drive evolution, but they can also be risky. New research led by plant biologists at the University of California, ...

Breast cancer advancements include targeted therapies, oral medications for ER-positive/HER2-negative populations, and ...

WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by their role in targeting DNA repair vulnerabilities.